- HIPRA announces the launch of a new CDMO unit, HIPRA Biotech Services, specialising in biological development and manufacturing for third parties.
- The new unit, based in the European Union, employs 1,400 professionals and aims to become “one of the largest of its kind” in Europe.
HIPRA, a biotechnology leader with over 50 years of experience, has expanded its operations with the launch of HIPRA Biotech Services, a Contract Development and Manufacturing Organisation (CDMO) unit. The new facility, located at the heart of the European Union, is designed to support the end-to-end development and manufacturing of biological products for third-party clients.
The facility will leverage HIPRA’s scientific and technical expertise across a wide range of biotechnology platforms, offering services spanning from research and development to large-scale commercial production.
Carlota Gómez de la Hoz, Global Chief Corporate Affairs and Sustainability Officer at HIPRA commented:
“This new unit called HIPRA Biotech Services encompasses the entire product lifecycle, from the early stages of research and development to large-scale commercial production, employs 1,400 highly specialized professionals and is expected to become one of the largest of its kind in Europe.”
Find out more on their website.
